Bray V J, West S G, Schultz K T, Boumpas D T, Rubin R L
Rheumatology Service, Fitzsimons Army Medical Center, Aurora, CO 80045-5001.
J Rheumatol. 1994 Nov;21(11):2157-8.
Two patients developed drug induced lupus secondary to sulfasalazine (SSZ). One patient was receiving SSZ for Crohn's disease and was subsequently treated with olsalazine, which lacks the sulfapyridine component of SSZ. Her inflammatory bowel disease (IBD) remained controlled and she did not develop a recurrence of lupus, suggesting that olsalazine is safe in patients with IBD and a history of SSZ induced lupus. The SSZ induced antibodies were predominantly IgG against the (H2A-H2B)-DNA complex. Since lupus induced by 7 other drugs was associated with a similar antibody response, our findings support the existence of a common pathway for autoantibody induction.
两名患者继发于柳氮磺胺吡啶(SSZ)出现药物性狼疮。一名患者因克罗恩病接受SSZ治疗,随后改用奥沙拉嗪治疗,奥沙拉嗪不含SSZ的磺胺吡啶成分。她的炎症性肠病(IBD)仍得到控制,且未出现狼疮复发,这表明奥沙拉嗪对患有IBD且有SSZ诱导性狼疮病史的患者是安全的。SSZ诱导产生的抗体主要是针对(H2A-H2B)-DNA复合物的IgG。由于其他7种药物诱导的狼疮也伴有类似的抗体反应,我们的研究结果支持自身抗体诱导存在共同途径。